Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - insulin glargine -

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, suspension - excipient ingredients: hydrochloric acid; zinc; metacresol; water for injections; glycerol; sodium chloride; protamine sulfate; sodium hydroxide; dibasic sodium phosphate dihydrate; phenol - treatment of diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, suspension - excipient ingredients: zinc; dibasic sodium phosphate dihydrate; protamine sulfate; metacresol; sodium chloride; sodium hydroxide; glycerol; phenol; hydrochloric acid; water for injections - treatment of diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: phenol; sodium chloride; sodium hydroxide; water for injections; hydrochloric acid; zinc; metacresol; dibasic sodium phosphate dihydrate; glycerol - treatment of diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: phenol; zinc; dibasic sodium phosphate dihydrate; sodium hydroxide; glycerol; metacresol; sodium chloride; water for injections; hydrochloric acid - treatment of diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: water for injections; metacresol; glycerol; sodium chloride; dibasic sodium phosphate dihydrate; hydrochloric acid; sodium hydroxide; zinc; phenol - treatment of diabetes mellitus.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

c p pharmaceuticals ltd - insulin soluble porcine; insulin isophane porcine - suspension for injection - 30unit/1ml ; 70unit/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - insulin glargine, quantity: 3.6378 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; metacresol; water for injections; zinc chloride; sodium hydroxide; glycerol - insulin glargine is an insulin analogue indicated for once-daily subcutaneous administration in the treatment of type 1 diabetes mellitus in adults and children and type 2 diabetes mellitus in adults who require insulin for control of hyperglycaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

maxx pharma pty ltd - insulin glargine, quantity: 100 u/ml - injection, solution - excipient ingredients: sodium hydroxide; glycerol; water for injections; hydrochloric acid; metacresol; zinc chloride - insulin glargine is an insulin analogue indicated for once-daily subcutaneous administration in the treatment of type 1 diabetes mellitus in adults and children and type 2 diabetes mellitus in adults who require insulin for the control of hyperglycaemia.

United States - English - NLM (National Library of Medicine)

imclone llc - insulin lispro (unii: gfx7qis1ii) (insulin lispro - unii:gfx7qis1ii) - insulin lispro injection is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. insulin lispro injection is contraindicated: - during episodes of hypoglycemia - in patients who are hypersensitive to insulin lispro injection or to any of its excipients. risk summary the limited available data with insulin lispro injection in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. published studies with insulin lispro used during pregnancy have not reported an association between insulin lispro and the induction of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data) . there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . pregnant rats and rabbits were exposed to insulin lispro in animal reproduction studies during organogenesis. no adverse effects on embryo/fetal viability or morphology were obser